Comparing the current results to its competitors, Vyne Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 40.58 % year on year. The sales growth was above Vyne Therapeutics Inc 's competitors' average revenue growth of 7.59 %, achieved in the same quarter.
Vyne Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 10.4 %
Vyne Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical and biotechnology firms, academic and research institutions, and government agencies. Competitors often possess greater financial resources and expertise in research and development, manufacturing, and clinical development. The company is also subject to governmental policies that encourage generic drug competition and lower pricing. Any product candidate developed by the company will compete with existing and emerging treatments. Additionally, smaller or early-stage companies may present significant competition, particularly through collaborative efforts.
Strong sales growth of 40.58 % in Overall company contributed to Vyne Therapeutics Inc increase in total revenue by 40.58 % Vyne Therapeutics Inc improved its market share in this segment, to approximately 0 %.
June 5, 2024
VYNE Therapeutics Advances Potential Treatment for Vitiligo with Phase 2b TrialBridgewater, N.J., January 10, 2024 - VYNE Therapeutics Inc. (Nasdaq: VYNE), a leading clinical-stage biopharmaceutical company specializing in immuno-inflammatory conditions, has recently made significant strides in the treatment of vitiligo. The company has announced the dosing of the first subject in a Phase 2b trial for their novel BET inhibitor, VYN201 gel. This trial aims to evaluate the efficacy and safety of once-daily application of VYN201 gel in individuals with either active or stable nonsegmental vitiligo.Vitiligo is a chronic skin disorder characterized by the loss of pigmentation, resulting in white patches that can ...
January 10, 2024
is pleased to document a milestone advance in the field of immuno-inflammatory conditions. On January 10, 2024, VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company poised at the forefront of medical innovation, disclosed a trove of encouraging biomarker data. These reported results stemmed from their dedicated Phase 1b trial, which explored treatments for nonsegmental vitiligo - a condition that till now has been notoriously challenging to treat.Vitiligo is a long-term dermatological condition characterized by patches of skin losing their pigment. Nonsegmental Vitiligo, also known as generalized or bilateral vitiligo, is the most common type, affecting seven out of every ten patients. This fo...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Sources:
Vyne Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vyne Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
